minnelide
Small moleculeexperimental
Triptolide is a diterpenoid epoxide which is produced by the thunder god vine, Tripterygium wilfordii. It has in vitro and in vivo activities against mouse models of polycystic kidney disease and pancreatic cancer, but its physical properties and severe toxicity limit its therapeutic potential. Consequently, a synthetic water-soluble prodrug, minnelide, is being studied clinically instead. — Wikipedia
Clinical trial activity
9 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2013 (NCT01927965)
Timeline
Indications
Mechanism of action
- Myc proto-oncogene proteinINHIBITOR
MYC inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)[C@]12O[C@H]1[C@@H]1O[C@]13[C@]1(O[C@H]1C[C@H]1C4=C(CC[C@@]13C)C(=O)OC4)[C@@H]2OCOP(=O)([O-])[O-].[Na+].[Na+]- Mol. weight
- 514.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- WikipediaTriptolide ↗
- ChEMBLCHEMBL3740500 ↗
Also known as
- 14-o-phosphonooxymethyltriptolide
- minnelide
- minnelide
- minnelide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05557851 | Phase 1 | Nov 1, 2022 | Minneamrita Therapeutics LLC, Sungkyunkwan University |
| NCT05166616 | Phase 1 | Mar 7, 2022 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT04896073 | Phase 2 | Dec 7, 2021 | National Cancer Institute (NCI) |
| NCT05566834 | Phase 1 | Nov 2, 2020 | Minneamrita Therapeutics LLC |
| NCT03760523 | Phase 1 | Apr 8, 2019 | Minneamrita Therapeutics LLC, University of South Florida |
| NCT03347994 | Phase 1 | Apr 30, 2018 | Minneamrita Therapeutics LLC, University of Miami |
| NCT03129139 | Phase 1 | Aug 1, 2017 | Minneamrita Therapeutics LLC, Translational Drug Development |
| NCT03117920 | Phase 2 | Apr 10, 2017 | HonorHealth Research Institute, Minneamrita Therapeutics LLC, University of London |
| NCT01927965 | Phase 1 | Aug 1, 2013 | Minneamrita Therapeutics LLC |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Minneamrita Therapeutics LLC | For profit | 7 | 4 | 2 | 2013 |
| National Cancer Institute (NCI) | Government | 2 | 1 | 2 | 2021 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2022 |
| HonorHealth Research Institute | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Sungkyunkwan University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Translational Drug Development | For profit | 1 | 0 | 1 | 2017 |
| University of London | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Miami | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of South Florida | Academic/Hospital | 1 | 1 | 1 | 2019 |
9 organizations
Page 1 / 1